Home›Trial›NCT06121297
🔬NCT06121297Phase 1Phase 2RECRUITING

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Study Summary

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Conditions
Systemic Lupus ErythematosusLupus Nephritis
Interventions / Drugs
CABA-201CABA-201
View on ClinicalTrials.gov ↗
Sponsor
CABA
Cabaletta Bio
Immunology
D48/100
Study Details
Enrollment28 participants
Primary Completion—
Lead SponsorCabaletta Bio
Data Retrieved2026-04-11 04:08:39.574104+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.